Corcept Therapeutics Incorporated reported $831M of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $831M (to Q2 2026). Net income: $55M, trailing twelve months to Q2 2026. Free cash flow: $107M, trailing twelve months to Q2 2026. Operating margin: −1.7%, trailing twelve months to Q2 2026.

CORTCorcept Therapeutics Incorporated

Healthcare

$121.12+50% 1Y

$121.12

$32.1552 weeks$123.53

CORT as reported

Corcept Therapeutics Incorporated reported $831M of revenue over the trailing twelve months, +16% on the year before. 11 reported series are charted on this page, each one as filed.

$831M

Revenue, trailing twelve months · to Q2 2026 · +16% against the twelve months before

Net income: $55M
Net income · −59% year on year · trailing twelve months to Q2 2026
Free cash flow: $107M
Free cash flow · −41% year on year · trailing twelve months to Q2 2026
Operating margin: −1.7%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CORT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$831M	+16%	Q2 2026
Net income	$55M	−59%	Q2 2026
EPS	$0.42	−63%	Q2 2026
Gross margin	98%	n/a	Q2 2026
Operating margin	−1.7%	n/a	Q2 2026
Net margin	4.8%	n/a	Q2 2026
ROE	12%	n/a	Q2 2026
ROA	9.2%	n/a	Q2 2026
ROIC	226%	n/a	Q4 2017 · 34 quarters behind
Free cash flow	$107M	−41%	Q2 2026
P/E	288	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.